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Abstract
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Background: Central sleep apnea (CSA) is a breathing disorder caused by the intermittent
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absence of central respiratory drive. Transvenous phrenic nerve stimulation is a new
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therapeutic option, recently approved by the FDA , for the treatment of CSA.
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Objective: To describe the technique used to implant the transvenous phrenic nerve
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stimulation system (the remedē System, Respicardia, Inc).
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Methods: The remedē System is placed in the pectoral region, typically on the right
side. A single stimulation lead is placed in either the left pericardiophrenic vein (PPV) or
the right brachiocephalic vein (RBC). A sensing lead is placed into the azygous vein to
detect respiration.
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Results: In the remedē System Pivotal trial, 147 of 151 (97%) patients were successfully
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implanted with the system. Sixty‐two percent of stimulation leads were placed in the PPV
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and 35% in the RBC. Mean procedure time was 2.7 ± 0.8 hours and 94% of patients were
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free from implant‐related serious adverse events through 6 months.
Conclusion: In patients with CSA, transvenous phrenic nerve stimulation is an
effective and safe therapy with an implant procedure similar to that of cardiac
implantable electronic devices.
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1 | BACKGROUND

2 | METHODS

Central sleep apnea (CSA) is a breathing disorder characterized

2.1 | Venous access

by periods of apnea or absence of airflow caused by absent
central respiratory drive because of increased sensitivity to the
partial pressure of CO 2.1 CSA commonly presents as Cheyne‐
Stokes breathing, characterized by cycles of deep, rapid,
crescendo decrescendo breathing (hyperpnea), followed by
slower, shallower breathing (hypopnea), or no breathing without
respiratory effort from the diaphragm (apnea). 1 Etiologies of CSA
include cardiovascular disease, stroke, chronic use of opioids,
renal disease, and idiopathic causes. The prevalence of CSA in
atrial fibrillation and heart failure is as high as 30% and 40%,
respectively.2,3 Moreover, a well‐established relationship exists

793

The implant procedure is performed in the electrophysiology laboratory
under conscious sedation as the patient and physician must communicate
during stimulation lead placement testing. Patient preparation and
antibiotics are similar to cardiac implantable electronic device (CIED)
implants.12 The remedē System guide catheter (Respiguide, Respicardia,
Inc) and stimulation leads are designed primarily for right‐sided access,
however, the system can be implanted on the patient's left side. Venous
access is obtained by means of the right axillary, cephalic, or subclavian
vein. Two long access wires (150 cm) are advanced into the inferior
vena cava.

between Cheyne‐Stokes respirations and increased mortality in
patients with heart failure.4-6 In addition to increased mortality,
the recurring hypoxemia and neurohormonal activation associated with CSA lead to systemic and pulmonary hypertension,
5,6

2.2 | Implantation of the stimulation lead
Transvenous phrenic nerve stimulation uses a stimulation lead implanted

To date,

adjacent either the left or right phrenic nerve that has multiple

treatment options for CSA have been limited, especially in

electrodes, which can be programmed in unipolar or bipolar configura-

patients with heart failure and reduced left ventricular function

tions. Depending on patient anatomical characteristics the left or right

where mask‐based therapies may, in fact, lead to an increase in

simulation lead (eg, respistim L, LQ, or LQS [left] lead or the respistim R

arrhythmias, and increased cardiovascular burden.

mortality (SERVE‐HF).

7,8

[right] lead, Respicardia, Inc) is implanted in either the left pericardio-

The remedē System is a novel implantable technology that is

phrenic vein (PPV) or right brachiocephalic vein (RBC), which run

FDA‐approved to treat moderate to severe CSA in adult patients.9

adjacent to the respective nerve. The left side is preferred because of

The remedē System is comprised of an implantable pulse generator

vessel size and relative proximity to the phrenic nerve. Stimulation is

(IPG), a stimulation lead for unilateral phrenic nerve stimulation, an

effective on either side with 60% and 53% of patients achieving >50%

optional sensing lead to detect respirations and a programmer. The

reduction in AHI with left and right stimulation leads, respectively.9

IPG is a programmable device that provides an electrical stimulus to

Placement of a left stimulation lead was attempted in all 151 patients

the left or right phrenic nerve and monitors the patient's respiration

enrolled in the remedē System Pivotal Trial (150 respistim LQS Model

using transthoracic impedance. Stimulation of the left or right

4065, 1 respistim LQ Model 5065). The LQ and LQS stimulation lead is a

phrenic nerve causes the diaphragm to contract, thereby developing

quadripolar, transvenous, over‐the‐wire lead with two IS‐1 terminal pins

negative intrathoracic pressure and restoring regular breathing

and four ring electrodes; the LQS has a preformed S‐shape bias at the

pattern.10

distal end. Classically, the PPV ostium is located below the left internal

Because of the lack of therapeutic options available for

jugular vein on the inferior aspect of the left brachiocephalic vein (LBC).

patients with CSA and the morbidity associated with the disease,

The procedures and techniques used to deploy the lead into the PPV are

phrenic nerve stimulation is an important treatment, especially

described below.

for patients with concomitant heart failure. The remedē System

To visualize the PPV, the 7 French (Fr) guide catheter is delivered

Pivotal Trial demonstrated significant improvements in the

over an access wire into the superior vena cava (SVC). Using the guide

number of sleep apnea events, sleep architecture, hypoxia, and

catheter and the access wire, the guide catheter is advanced into the

arousals (all P < 0.001). The safety profile demonstrated a 91%

LBC (Video S1), and the tip is positioned at the junction of the left

freedom from adverse events associated with the implant

subclavian and LBC veins (Figure 1A). With the guide catheter and

procedure, the remedē System, or delivered therapy through

inner catheter oriented towards the floor of the LBC, a nonselective

the 12‐month visit. Further, the study showed significant

contrast injection is performed to identify venous branches (Figure 1B;

improvements in patient's quality of life as measured by the

Videos S2 & S3). Then, a 5 Fr inner catheter (Merit Medical, Model #

Epworth Sleepiness Scale and Patient Global Assessment.9

57538CSV‐WOR) is advanced into the guide catheter. The inner

Recently, improvements were seen at 12 months in ejection

catheter telescopes beyond the guide catheter and is oriented towards

fraction, Minnesota Living with Heart Failure Questionnaire, and

the LBC floor, the entire assembly is slowly dragged medially while

a

failure

monitoring the catheter tip for deflection into a branch vein.

hospitalization. 11 This article describes the implant techniques

Alternatively, the area below the internal jugular vein is examined

trend

towards

increased

time

to

first

heart

and experience of this important new therapeutic modality for

by gentle probing with a 0.014” coronary wire (Figure 2A; Video S4)

the treatment of CSA.

and/or bolus of contrast. Contrast used during this step of the
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F I G U R E 1 A, Guide catheter at the junction of the left brachiocephalic (LBC) vein and left subclavian veins. B, Nonselective venogram
showing branches taking off from the LBC vein
procedure should be undiluted. Visualization of the PPV ostium should

Once the PPV is visualized and the vessel is accessed using a

be performed cautiously by hand to avoid venous dissection or

0.014” coronary wire, the wire is passed to the level of the cardiac

contrast extravasation, which may render access and visualization of

apex. Instructing the patient to make several deep breaths can

the PPV difficult.

facilitate advancement of the wire along the length of the PPV (Video

While the PPV ostium is most frequently on the floor of the

S5). Deep breathing expands the thorax and lengthens the PPV,

LBC, some variability exists, and it can be located up to 40 degrees

resulting in a momentary reduction of the vessel's tortuosity and

13

increased venous volume that helps to open valves. With the support

Using puffs of contrast in the left anterior oblique (LAO)

of the wire placed deep in the PPV and the additional support of the

projection, the PPV ostium can be visualized in relation to the

inner catheter, the guide catheter is advanced and stabilized within

internal thoracic and left superior intercostal veins. The PPV runs

the PPV ostium. The inner catheter is then removed while

along the border of the mediastinum and lies within the parietal

maintaining a deep apical position of the coronary wire. The

pericardium until it reaches the cardiac apex. The vein is generally

stimulation lead is deployed by back loading the lead onto the

isodiametric along its entire length and is known to have valves 1

coronary wire and navigating the lead through the guide catheter

to 2 cm inferior to the ostium. The anatomy of the PPV is variable;

into the PPV to the level of the left atrium (Figure 2B; Videos S6 &

presentations include a shared common ostium with the internal

S7). Once the stimulation lead is placed in the desired location, the

thoracic vein and a shared common ostium with the left superior

guide wire is retracted sufficiently to expose the lead bias that

intercostal vein.

passively stabilizes the lead in the vessel.

posteriorly or anteriorly. The PPV ranges in size from 3 to 6 Fr.

F I G U R E 2 A, Probing with the 0.014” coronary wire and cannulating the pericardiophrenic vein. B, Deploying the left stimulation leads to
the level of the left atrium
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F I G U R E 3 A, Orientation of the coronary sinus right catheter in the superior vena cava to identify the azygos ostium. B, Contrast injection
through an inner catheter revealing the azygos ostium and valve leaflets (left anterior oblique)

2.3 | Implantation of the sensing lead
Once the stimulation lead is deployed, the sensing lead is implanted
into the azygos vein or one of its lateral branches. The sensing lead
can be any 6 Fr bipolar lead with a passive fixation bias, based on
implanting physician preference. The sensing lead detects respiration
by means of transthoracic impedance. The sensing lead is an optional
lead. There was no difference in therapy effectiveness or safety
outcomes in patients with or without dedicated sensing lead during
the pivotal trial. One benefit of a dedicated sensing lead is that
remedē System diagnostic software tools may display information
with higher respiratory signal quality, which may reduce the number
of patient visits needed during therapy titration.
Using the second venous access wire, a 9 Fr coronary sinus (CS)
right guide catheter is delivered into the SVC to a level midway
between the tracheal carina and junction of the brachiocephalic veins.
In the anterior‐posterior (AP) projection, the tip of the guide catheter is
oriented toward the lateral aspect of the SVC (Figure 3A; Video S8). To

FIGURE 4

best visualize the ostium of the azygos vein, the fluoroscope projection
should be changed from AP to LAO 30 to 45° or right anterior oblique
30 to 40° and a bolus of contrast delivered. Alternatively, using a 5 Fr
Azygous Right inner catheter (eg, Merit medical, Model # 1628‐043), in
an LAO projection, the azygos ostium can be visualized with a bolus of
contrast delivered with the tip oriented toward the spine (Figure 3B;
Video S9). Access to the vein is accomplished by orienting the inner
catheter toward the ostium and a 0.035” × 150 cm wire (eg, Glidewire,
Terumo Medical, Ann Arbor, MI) is advanced into the azygos vein. The
wire is directed around the azygos arch deep into the azygos vein to
the level of the diaphragm. A valve is usually encountered in the arch
and is frequently traversed by prolapsing the wire tip and employing
the same deep breathing or coughing maneuvers described during
deployment of the left stimulation lead. The inner catheter is advanced
over the wire followed by the 9 Fr guide catheter (Video S10).
Once the guide catheter is advanced to a depth midway between the
diaphragm and azygos vein ostium, the 0.035” wire is removed and a
venogram is performed to confirm cannulation of the azygos vein and to

A, Venogram of the azygos vein revealing branch vein ostia. B, Cannulation of the branch vein using a 0.014” coronary wire
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A, Venogram of the target branch off the azygos vein. B, Location of the sensing lead in the branch vein

visualize the ostium of the targeted right lateral branch of the vein
(Figure 4A; Video S11). The branch vein is cannulated using a new 0.014”
coronary wire and an inner catheter. The same inner catheter used
during placement of the stimulation lead can be used to subselect the
branch off the main tributary of the azygos vein (Figure 4B; Videos S12 &
S13). The inner catheter can be used for a selective contrast injection to
confirm the course and caliber of the branch vein. (Figure 5A; Video S14).
Subsequently, the 9 Fr guide catheter is advanced up to or into the
branch in preparation for delivery of the sensing lead. The inner catheter
is then removed and the sensing lead is back loaded onto the 0.014” wire
and advanced into the side branch, positioning the electrodes 7 to 10 cm
lateral to the spine (Figure 5B; Video S15). No electrical testing of the
sensing lead is needed. Using the 0.014” coronary wire to stabilize the
lead, the guide catheter is removed using a slitter and standard coronary
sinus catheter removal techniques. The sensing lead is stabilized using the
ligature sleeve.

FIGURE 6

ET AL.

2.4 | Testing for adequate phrenic nerve capture
Final positioning of the stimulation lead electrodes at the level of the left
atrium occurs before stimulation testing using the phrenic nerve
stimulation programmer and external IPG (eIPG; Respicardia, Inc). The
programmer is comprised of a touch screen tablet computer and an
external programming wand. The wand connects to the programmer via
USB and provides a communication link to the CIED. When placed over
the IPG the wand uses inductive telemetry for configuration of
programmable settings, initiation of system testing, and review of
diagnostic data. The eIPG is used for evaluation of stimulation lead
placement during implantation. Stimulation testing requires communication with the patient to ensure an appropriate stimulation response. For
this reason, general anesthesia is not used during implantation.
Assessment of lead placement and its proximity to the left phrenic
nerve is performed by selecting an electrode configuration (cathode–
anode electrode pair) and making connections to the eIPG using the

A, Final position of the left stimulation and sensing leads. B, Placement of the right‐sided stimulation lead
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T A B L E 1 Implant procedure data
Lefta

Right

Pooledb

Variables

(n = 94)

(n = 53)

(n = 151)

Implant duration, h

2.5 ± 0.7 (94)
2.4 (1.3, 5.3)

3.2 ± 0.8 (53)
3.1 (1.6, 6.2)

2.7 ± 0.8 (151)
2.6 (1.3, 6.2)

Total fluoroscopy, min

33.1 ± 16.6 (93)
32.0 (4.0, 89.0)

59.2 ± 22.2 (53)
56.0 (27.0, 126.0)

43.0 ± 22.5 (150)
40.0 (4.0, 126.0)

Total contrast, mLc

48.2 ± 48.6 (94)
35 (5, 400)

74.8 ± 61.1 (53)
60.0 (14, 350)

58.2 ± 55.4 (151)
45 (5, 400)

100% (94/94)
N/A
0% (0/94)
97% (91/94)

0% (0/53)
N/A
100% (53/53)
26% (14/53)

62% (94/151)
3% (4/151)
35% (53/151)
70% (105/151)

Stimulation lead placement
Left
None
Right
Sensing lead implanted

Mean ± SD (n)/median (min, max)
Patients are counted on the side of the successful lead implanted at the initial implant attempt. Any effort on the opposite side is included as cumulative
for the implant attempt.
b
Pooled includes four subjects with unsuccessful implant attempts.
c
Use of a power injector for administering contrast.
a

test cable. Stimulation lead impedance is measured using the
programmer followed by stimulation threshold testing. Delivering
single bursts 2 seconds in duration; the stimulation amplitude is
incrementally decreased or increased to achieve a moderately strong
and full contraction of the diaphragm as determined by means of
abdominal palpation or fluoroscopy (Video S16). If complete contraction of the hemidiaphragm cannot be achieved, a new electrode pair is
selected, or the stimulation lead is repositioned. If during testing, the
patient experiences extra respiratory sensations (ERS), defined as
twitching, tingling, or diffuse discomfort in the ipsilateral shoulder or
neck either with or without diaphragmatic contraction, another
electrode pair is selected or the lead is repositioned. Using 20‐Hz
and 150‐microsecond pulse width, 4 mA current or less, typically
elicits a moderately strong to strong diaphragmatic contraction. Using
the 0.014” coronary wire to stabilize the lead, a slitter is used to cut
and remove the catheter. The stimulation lead is stabilized using two
manufacturer's ligature sleeves with a recommended minimum 10 cm
of stress relieving loop between the sleeves. The IPG and implanted
leads are connected using setscrews. The IPG is placed in a
subcutaneous pocket in the mid infraclavicular area and secured in
place with a single ligature using a suture hole through the IPG header.
The final positions of both the left stimulation and sensing leads are
shown in Figure 6A; Video S17).

2.6 | Alternate approach
In some patients, the left stimulation lead was not implanted because of
the inability to visualize the PPV, inadequate size of the vessel, the
presence of valves, or vessel tortuosity. In these situations, a stimulation
lead can be implanted on the right side. Using one of the previously
placed venous access wires, an 8 Fr splittable hemostatic introducer is
placed into the RBC. A venogram of the RBC and SVC is performed to
understand the shape and diameter of the vessel. The respistim R lead is
a multipolar, transvenous, stylet‐delivered lead. The proximal end of the
lead has IS‐1 terminal pins and the distal end of the lead comprises
multiple ring electrodes and a helical shape bias. With the stylet fully
advanced to straighten the helical bias, the lead is inserted through the
introducer and advanced deep into the SVC; the stylet is then retracted
to let the helical bias form within the vessel. The lead is retracted while
applying counter‐clockwise rotation until the helices are located in the
RBC and upper portion of the SVC and electrodes are oriented on the
right lateral aspect of the vessel (Figure 6B). Electrode stability is
assessed by instructing the patient to take several deep breaths and
make several deep coughs while observing the electrodes using
fluoroscopy. If the electrodes appeared unstable, the lead is relocated
within the vessel to find the position in which the lead helix is most
relaxed and captures the right phrenic nerve. The right stimulation lead is
stabilized in the pectoral region using the same methods described for
the left stimulation lead.

2.5 | Device activation and operation
After a 1‐month period allowed for healing and lead maturation, patients
undergo therapy initiation. Therapy is programmed to automatically

3 | R ES U L T S FR O M T H E R EM ED Ē SY S TEM
PIVOTA L TRIAL

begin when the patient is in a sleeping position, at rest during their
normal sleep hours, and after lead impedance is measured. Individualized

Of the 151 randomized patients enrolled in the remedē System Pivotal

device settings, including therapy start/stop times and programmed

Trial, 147 (97%) were successfully implanted on the first attempt. The

stimulation parameters, are determined by in‐office testing, interviewing

four patients who did not successfully receive an implant had anatomical

the patient regarding sleep habits and, when necessary, monitoring

variability. Ninety‐four (62%) of the 151 patients were implanted with left

patient response to overnight stimulation.

stimulation leads; 53 (35%) had right stimulation leads implanted. One
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sensing lead, 92 out of 94 left lead patients and 16 of the 53 right lead
patients. A dedicated sensing lead provided the highest quality sensing
10

10

9

10

7

signal; implantation was an optional subject to physician discretion. The
9

Maximum(mA)

hundred and five (70%) of the 151 patients were implanted with a

percentage of patients free from serious adverse events associated with
the implant procedure, the system, or the delivered therapy through the
12‐month visit was 91% (95% confidence interval [86%, 95%]).9

patients during implantation. All were resolved with repositioning of the

1.7

2.0

3.5

0.8

1.0

lead during the procedure or through the use of alternate electrodes at
0.9

Minimum(mA)

During implantation, ERS in the ipsilateral shoulder or neck with or
without diaphragmatic contraction was detected in 11 of 151 (7%)

the time of therapy initiation.
The average overall procedure time (skin to skin) was 2.7 ± 0.8 hours
saw a 45‐minute reduction in procedure time as well as decreases in the
quantity of fluoroscopy time and contrast volume. Implant duration,
fluoroscopy time, and amount of contrast used are summarized in
Table 1. Phrenic nerve capture parameters at implant (month 0), 1 month,
and 6 months after implant are shown in Table 2.

2.5

2.3

1.9

1.6

1.3

A concomitant CIED was previously implanted in 64 (47%) patients.
1.6

Standarddeviation (mA)

from the first incision to final suture. Implanters with seven or more cases

Patients with concomitant CIEDs undergo testing at the time of implant.
During the trial, there was one shock delivered by an implantable
reprogramming of the ICD. This incident resulted in changes in the

5.0

5.5

7.0

2.5

3.0

testing procedure. There were no incidents of pacing inhibition.
2.5

Median(mA)

cardiac defibrillator because of oversensing, which was resolved by

The remedē System implant procedure was done by electrophysiologists

5.3

5.6

6.6

2.9

3.0

and previously shown to be safe, in part, because of the similarity of the
3.0

Mean(mA)

4 | D I S C U SS I O N

procedure to contemporary methods and techniques used to implant
CIEDs. While the anatomical targets for lead placement are distinct from
those of CIEDs, the size and type of guide wires, and the type and
functionality of the catheters are the same as those used for implanting a

47

51

53

84

94

91

n

(eg, advancing the lead while retracting the wire) to the new anatomical
locations are similarly familiar to electrophysiologists experienced in
biventricular CIED implants. A procedure‐related complication rate of 6%
is similar to the 8.6% left ventricular lead‐related complications occurring

6 mo

1 mo

Implant

6 mo

Implant

1 mo

Visit

in patients with biventricular CIEDs at a similar stage of development and
4% perioperative complications later reported in the REsyncronization
reVErses Remodeling in Systolic left vEntricular dysfunction trial.14,15
While there was one venous dissection associated with insertion of the
catheter in the subclavian vein, this AE did not occur with cannulation of
the PPV or brachiocephalic veins and resolved without sequelae.
The energy delivered by the phrenic nerve stimulator is different
from that of a CIED. The output applied to the phrenic nerve is a burst of
pulses (60‐300–microsecond pulse width at 10‐40 Hz frequency) having

Right

varying amplitude that produce a smooth diaphragmatic contraction
Left

Stimulation lead tested

T A B L E 2 Capture current soliciting as a strong response

biventricular CIED. The techniques and means for navigation of the lead

similar to that occurring with a normal breath, not the “hiccup” response
that occurs when a left ventricular lead of a cardiac resynchronization
device stimulates the phrenic nerve. The recurring smooth diaphragmatic
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contraction enables the resumption of a normal breathing pattern and
16

stabilization of blood carbon dioxide levels.

By stabilizing carbon

dioxide, phrenic nerve stimulation prevents apneic events and the
subsequent periods of rapid breathing. Sensing of this respiration pattern
is accomplished by programming a sensing vector using either the
stimulation lead or sensing lead. The vector is determined at therapy
initiation at which time various sensing vectors are evaluated.
Compared to the surgical implantation of a cuff electrode, the
transvenous approach eliminates the risk of damage to the nerve, cuff‐
related neural compression, and impairment of blood flow that can lead
to degeneration and demyelination of axons. Furthermore, the transvenous approach offers the patient a rapid and comfortable recovery. The
mean procedure time of 2.7 hours and the improvement in procedure
time with growing experience commensurate with that previously
reported.17 The practicality and safety of implanting the remedē system
permits the delivery of the only therapy that to date has been proven in a
randomized controlled trial to ameliorate CSA and mitigate its harmful
consequences.8

5 | CONC LU SION
Phrenic nerve stimulation is a safe and novel means for the
treatment of CSA. The transvenous implantation technique of the
remedē System is very similar to CIED procedures utilizing
instruments and techniques familiar to electrophysiologists. The
ability to implant the remedē System enables the only therapy shown
to meaningfully improve CSA and its detrimental clinical sequelae.
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SU PP ORT IN G IN FOR M ATI O N
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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